Alpine Immune Sciences Inc
NASDAQ:ALPN 4:00:00 PM EDT
| Market Cap (Intraday) | 865.35M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $13.84 |
| 50-Day MA | $11.72 |
| 200-Day MA | $10.42 |
Alpine Immune Sciences Inc Stock, NASDAQ:ALPN
188 East Blaine Street, Suite 200, Seattle, Washington 98102
United States of America
Phone: +1.206.788.4545
Number of Employees: 126
Description
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.